Journal
NPJ BIOFILMS AND MICROBIOMES
Volume 3, Issue -, Pages -Publisher
NATURE RESEARCH
DOI: 10.1038/s41522-017-0034-1
Keywords
-
Categories
Funding
- National Science Foundation [OCE 1435993]
- predoctoral Training Program in Cellular and Molecular Biology and Genetics [5T32GM007491-41]
Ask authors/readers for more resources
It is well appreciated that microbial metabolism of drugs can influence treatment efficacy. Microbial beta-glucuronidases in the gut can reactivate the excreted, inactive metabolite of irinotecan, a first-line chemotherapeutic for metastatic colorectal cancer. Reactivation causes adverse drug responses, including severe diarrhea. However, a direct connection between irinotecan metabolism and the composition of an individual's gut microbiota has not previously been made. Here, we report quantitative evidence of interindividual variability in microbiome metabolism of the inactive metabolite of irinotecan to its active form. We identify a high turnover microbiota metabotype with potentially elevated risk for irinotecan-dependent adverse drug responses. We link the high turnover metabotype to unreported microbial beta-glucuronidases; inhibiting these enzymes may decrease irinotecan-dependent adverse drug responses in targeted subsets of patients. In total, this study reveals metagenomic mining of the microbiome, combined with metabolomics, as a non-invasive approach to develop biomarkers for colorectal cancer treatment outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available